Aptevo Therapeutics (APVO) Short Interest Ratio & Short Volume

Short interest is the volume of Aptevo Therapeutics shares that have been sold short but have not yet been covered or closed out. As of May 15th, investors have sold 54,000 shares of APVO short. 1.33% of Aptevo Therapeutics' shares are currently sold short. Learn More on Aptevo Therapeutics' current short interest.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Aptevo Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.33% of Aptevo Therapeutics' floating shares are currently sold short.

Aptevo Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 54,000 shares, a decline of 79.9% from the previous total of 268,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Aptevo Therapeutics currently has issued a total of 4,080,000 shares. Some of Aptevo Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Aptevo Therapeutics currently has a public float of 4,070,000 shares.

1.33% of Aptevo Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Aptevo Therapeutics: Guardion Health Sciences, Inc. (14.30%), Avalo Therapeutics, Inc. (8.07%), Vaxxinity, Inc. (3.61%), Galera Therapeutics, Inc. (6.09%), Monopar Therapeutics Inc. (0.89%), Moleculin Biotech, Inc. (1.53%), Kintara Therapeutics, Inc. (2.04%), Eterna Therapeutics Inc. (1.89%), Aeterna Zentaris Inc. (0.53%), Chemomab Therapeutics Ltd. (0.88%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks.

Short selling APVO is an investing strategy that aims to generate trading profit from Aptevo Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Aptevo Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of APVO, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including APVO, twice per month. The most recent reporting period available is May, 15 2024.